The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Genetic mutations as poor prognostic indicators of HCT in venetoclax-treated AML
Yuho Najima, MD, PhD, Komagome Hospital, Tokyo, Japan, discusses the outcomes of hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) patients treated with venetoclax-based bridging therapy. Genetic analysis through next-generation sequencing (NGS) identified TP53 and kinase-related gene mutations as poor prognostic indicators, but venetoclax-based therapy was found to enhance outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
